Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2011-01-18
2011-01-18
Flood, Michele (Department: 1655)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094630, C435S212000, C435S215000, C435S217000
Reexamination Certificate
active
07871608
ABSTRACT:
A method of treating a subject, the method including administring a composition that includes a reversibly inactivated acidfied plasmin substantially free of a plasminogen activator, in a low buffering capacity buffer, wherein the composition is a solution suitable for pharmacenutical use that can be raised to physiological pH by adding no more than about 5 volumes of serum to the solution relative to a volume of the solution.
REFERENCES:
patent: 3136703 (1964-06-01), Singher
patent: 3434929 (1969-03-01), Buck et al.
patent: 3865692 (1975-02-01), Holleman et al.
patent: 3950223 (1976-04-01), Yugari et al.
patent: 3950513 (1976-04-01), Jensen
patent: 4082612 (1978-04-01), Robbins et al.
patent: 4115551 (1978-09-01), Lormeau et al.
patent: 4177262 (1979-12-01), Lormeau et al.
patent: 4259448 (1981-03-01), Nakamura et al.
patent: 4361652 (1982-11-01), Uemura et al.
patent: 4361653 (1982-11-01), Watanabe et al.
patent: 4418052 (1983-11-01), Wong
patent: 4442213 (1984-04-01), Heber et al.
patent: 4446316 (1984-05-01), Chazov et al.
patent: 4462980 (1984-07-01), Diedrichsen et al.
patent: 4499073 (1985-02-01), Tenold
patent: 4663146 (1987-05-01), Morser et al.
patent: 4774087 (1988-09-01), Wu et al.
patent: 4908204 (1990-03-01), Robinson et al.
patent: 5024829 (1991-06-01), Berger et al.
patent: 5068106 (1991-11-01), Paques et al.
patent: 5096637 (1992-03-01), DiLeo et al.
patent: 5112609 (1992-05-01), Johnston et al.
patent: 5165912 (1992-11-01), Selmer et al.
patent: 5237050 (1993-08-01), Boyle et al.
patent: 5288489 (1994-02-01), Reich et al.
patent: 5290692 (1994-03-01), Suzuki et al.
patent: 5304383 (1994-04-01), Eibl et al.
patent: 5328996 (1994-07-01), Boyle
patent: 5371007 (1994-12-01), Linnau et al.
patent: 5407673 (1995-04-01), Reich et al.
patent: 5407678 (1995-04-01), Rose et al.
patent: 5472692 (1995-12-01), Liu et al.
patent: 5587291 (1996-12-01), Binder
patent: 5728674 (1998-03-01), Sprecher et al.
patent: 5767269 (1998-06-01), Hirsh et al.
patent: 5776452 (1998-07-01), Eibl et al.
patent: 5879923 (1999-03-01), Yago et al.
patent: 5928218 (1999-07-01), Gelbfish
patent: 6139819 (2000-10-01), Unger et al.
patent: 6207066 (2001-03-01), Trese et al.
patent: 6355243 (2002-03-01), Novokhatny et al.
patent: 6479253 (2002-11-01), Silver et al.
patent: 6694764 (2004-02-01), Eckstein, Jr. et al.
patent: 6969515 (2005-11-01), Jesmok et al.
patent: 1 167 823 (1997-12-01), None
patent: 3617753 (1986-12-01), None
patent: 0256836 (1987-08-01), None
patent: 0256836 (1988-02-01), None
patent: 0297294 (1989-01-01), None
patent: 0 399 321 (1990-11-01), None
patent: 904478 (1962-08-01), None
patent: 985498 (1965-03-01), None
patent: 2 090 599 (1982-07-01), None
patent: 0207 8633 (1990-03-01), None
patent: 09 065895 (1997-03-01), None
patent: 103 682 (1991-12-01), None
patent: WO 87/06836 (1987-11-01), None
patent: WO 93/15189 (1993-08-01), None
patent: WO 95 04077 (1995-02-01), None
patent: WO 97/15572 (1997-05-01), None
patent: WO 98/37086 (1998-08-01), None
Abe, et al., “Immobilized urokinase column as part of a specific detection system for plasminogen species separated by high-performance affinity chromatography,” J. Chromatography, 1991, vol. 565, pp. 183-195.
Ambrus, et al., “Clinical and experimental studies on fibrinolytic enzymes,” Ann NY Acad Sci., Aug. 30, 1957, vol. 68, No. 1, pp. 97-137.
Amris, et al., “Clinical studies on an activator free porcine plasma (plasmin-novo),” Sangre (Barc), 1964, vol. 61, pp. 12-18.
Deacon, et al., “Technetium 99m-plasmin: a new test for the detection of deep vein thrombosis,” Eur J. Nucl. Med., 1980, vol. 53, No. 631, pp. 673-677.
Gottfried Schmer, “The purification of bovine thrombin by affinity chromatography on benzamidine-agarose,” Hoppe Seyler's Z Physiol Chem., May 1972, vol. 353, pp. 810-814.
Greig, et al., “Protamine-Heparin complex as a substrate for plasmin,” Biochim. Biophys, Acia., 1963, vol. 67, pp. 658-668.
In “Pharmaceutical Enzymes” (eds. R. Ruyssen & A. Lauwers)-Story Scientia, Gent, Belgium, 1978, pp. 124-131.
Owunwanne, et al., “Technetium Tc 99m plasmin in the diagnosis of inflammatory disease,” Eur J. Nucl. Med., 1987, vol. 12, No. 10, pp. 496-499.
Shi, et al., “Differential autolysis of human plasmin at various pH levels,” Thrombosis Research, 1988, vol. 51, pp. 355-364.
Shimura, et al., “High-performace affinity chromatography of plasmin and plasminogen on a hydrophilic vinyl-polymer gel coupled with p-aminobenzamidine,” J. Chromatography, 1984, vol. 292, pp. 369-382.
S. Shaukat Husain, “A single-step separation of the one-and two-chain forms of tissue plasminogen activator1,” Arch Biochem Biophys., 1991, vol. 285, pp. 373-376.
Alkjaersig, N., et al., “The Activation of Human Plasminogen,”J. Biol. Chem., 233(1): 81-85 (1958).
Alkjaersig, N., et al., “The Mechanism of Clot Dissolution by Plasmin,”J. Clin. Invest., 38(7): 1086-1095 (1959).
Ambrus, C., et al., “Insolubilized Activators of the Fibrinolysin System,”J. Med. 3:270-281 (1972).
Ambrus, J.L., et al., “Clinical Pharmacology of various types of fibrinolytic enzyme preparations,”Am. J. Cardiol., 6:462-475 (1960).
Amris, C.J., et al., “Effect of Plasmin Therapy on Blood Coagulation and on Plasma Proteins in Patients with Cancer,”Danish Medical Bulletin, 11(5):141-145 (1964).
Amris, C.J., et al., “Turnover and Distribution of131I-Labelled Procine Plasmin in Man and Dog,”Danish Medical Bulletin, 11(5):146-152 (1964).
Anlyan, W., et al., “Experiences with Fibrinolysin in Peripheral Vascular Occlusive Disease,”Am. J. Cardiol., 6:507-512 (1960).
Barrett, A.J., et al., “The Electrophoretically ‘Slow’ and ‘Fast’ Forms of the α2-Macroglobulin Molecule,”Biochem. J., 181:401-418 (1979).
Becker, Gary J., “Local Thrombolytic Therapy: Bridging the ‘Generation Gap,’”Am. J. Roentgenol., 140(2): 403-405 (1983).
Binder, B.R., et al., “Purification and Characterization of Human Vascular Plasminogen Activator Derived from Blood Vessel Perfusates,”Journal of Biological Chemistry, 254(6):1998-2003 (1979).
Boucek, R., et al., “Segmental Perfusion of the Coronary Arteries with Fibrinolysin in Man Following a Myocardial Infarction,”Am. J. Cardiol., 6:525-533 (1960).
Boyles, P.W., et al., “Comparative effectiveness of intravenous and intra-arterial fibrinolysin therapy,”Am. J. Cardiol., 6:439-446 (1960).
Castellino, F.J. and J.R. Powell, “Human Plasminogen,”Meth. Enzymology, 80:365-378 (1981).
Castellino, F.J., et al., “Rabbit Plasminogen and Plasmin Isozymes,”Methods in Enzymology, 45:273-286 (1976).
Collen D., et al., “Thrombolysis with human extrinsic (tissue-type) plasminogen activator in rabbits with experimental jugular vein thrombosis. Effect of molecular form and dose of activator, age of the thrombus, and route of administration,”J. of Clin. Invest., 71(2):368-376 (1983).
Deutsch, D.G. and E.T. Mertz, “Plasminogen: purification from human plasma by affinity chromatography,”Science170:1095-1096 (1970).
Freitag, H., et al., “Lys-plasminogen as an Adjunct to Local Intra-arterial Fibrinolysis of Carotid Territory Stroke: Laboratory and Clinical Findings,”Neuroradiology, 38:181-185 (1996).
Hedner, U., et al., “Effects of Porcine Plasmin on the Coagulation and Fibrinolytic Systems in Humans,”Blood, 51(1):157-164 (1978).
Holmberg, L., et al., “Purification of Urokinase by Affinity Chromatography,”Biochim. Biophys. Acta., 445: 215-222 (1976).
Jespersen, J., et al., “The autodigestion of human plasmin follows a bimolecular mode of reaction subject to product inhibition,”Thromb. Res. 41(3):395-404 (1986).
Johnson, A.J., et al., “Assay methods and standard preparations for plasmin, plasminogen and urokinase in
Colandene James
Jiang Shan
Novokhatny Valery
Zimmerman Thomas P.
Flood Michele
Talecris Biotherapeutics, Inc.
Womble Carlyle Sandridge & Rice PLLC
LandOfFree
Reversibly inactivated acidified plasmin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Reversibly inactivated acidified plasmin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reversibly inactivated acidified plasmin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2626690